RABEPRAZOLE 20 MG + LEVOSULPIRIDE 75 MG SUSTAINED RELEASE PELLETS CAPSULES is a multi particulate pharmaceutical formulation combining rabeprazole and levosulpiride within a capsule-based pellet system. The dosage form is developed around controlled pellet processing rather than conventional tablet compression, making pellet size, drug layering, coating uniformity, and capsule filling important stages of manufacturing. The two active ingredients also require careful formulation planning because their physical and chemical properties can differ significantly. For manufacturers developing a structured PCD Pharma Franchise portfolio, this type of specialized capsule requires controlled processing and detailed quality evaluation.
Imagine a capsule filling with thousands of small, highly active pellets. The concept is the same with, in which multiple small pellet units are contained within a capsule shell. This provides a formulation with flexibility, as each pellet can be individually layered with functional coatings before being filled into a capsule shell.
The protective wall of rabeprazole pellets is formed on the principle of the active substance's stability, whence the design of the pellets of levosulpiride considers the phenomenon of controlled release. Pellet technology deposits all active ingredients separately, which allows the distinct preparation of the coating system and control over the properties of each pellet group.
A typical path starts with a starter core or just an established palletization platform. The active is coated onto the mix by means of a carefully controlled layering or palletization process with pharmaceutical-grade excipients. Aspects such as particle size, surface topology, moisture level, density, and mechanical strength are all critical for the coating and capsule-filling process, requiring well-controlled production of pellets with a consistent size and characteristics.
Optimization of the amount of binder used and the preparation of the coating suspension, pump rate, spray rate, drying conditions, and processing time is fundamental in development. RABEPRAZOLE 20 MG + LEVOSULPIRIDE 75 MG SUSTAINED RELEASE PELLETS CAPSULES
The beauty of sustained release, is in the coating of the pellet population. Once a working polymeric coating is added, it is designed to serve as a controlled release barrier to release the active ingredient based on a profile. Coating consistency is critical, where differences in film weight can have an impact on the dissolution profile. The team tracks coating weight gain, spray conditions, product temperature, atomization, and drying efficiency.
Additional protective coating for rabeprazole pellets can be performed in accordance with the product development plan. The resulting formulation structure may be positioned to have "layers" for different functions. Then the suitable formulation product is ready for capsule filling, which involve tests for surface protection, size distribution, flowability, and release.
Individual pellet groups are mixed according to the approved formulation ratio once they adhere to the designated quality specifications. Since each pellet group has a distinct density and surface texture, the behavior in blending should be carefully checked, to avoid its segregation. During capsule-filling process, equipment is configured according to the desired weight and physical criteria for capsule fill of pellets. In-process control focus on weight variation, fill uniformity, capsule shell integrity, locking and visual appearance.
Related to the nature of the environment in which the material is present, humidity may adversely affect coated pellets and capsule shells, or mechanical handling may, by virtue of fragile particles, cause damage. The transfer of material and the manufacturing conditions are hence controlled to ensure product consistency.
Evaluation of these capsules involves comprehensive analysis of active substances and the entire multi particulate dosage form. This includes identification tests, assay, tests for related substances, uniformity of dosage units, and others as specified.
Dissolution testing of sustained-release pellets involves testing samples at pre-determined times during release to check release profile against specification. Stability of the pellets involves following variations in assay, degradation products, dissolution, appearance, coating, shell and moisture over the shelf life, and the effects of the packaging system on the pellet system are also monitored in stability development.
Packaging is the protector, shielding the capsule and its pellet system from the environment throughout the storage and distribution process. Blister packs, strips, and other high-barrier materials are tested for moisture transmission and stability considerations. Packaging development includes evaluation of seal, moisture transmission, capsule compatibility, and physical protection during distribution; batch coding and traceability support systematic management of the pharmaceutical supply chain.
RABEPRAZOLE 20 MG + LEVOSULPIRIDE 75 MG SUSTAINED RELEASE PELLETS CAPSULES for Pharma Franchise for Pharmaceutical is a perfect blend of multi particulate technology and controlled release technology for a specialized PCD Pharma Franchise Portfolio. Key features for PCD Pharma Franchise are uniform production of pellets, meticulous coating, assured capsules filling, analytical testing, and safety packaging as a consolidated finished product.
Rabeprazole 20mg + Levosulpiride 75mg SR Pellets Capsules with formulation, pellet technology, manufacturing, quality control and packaging details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech